Primary Care COPD Patients Compared with Large Pharmaceutically-Sponsored COPD Studies : An UNLOCK Validation Study
Annemarije L Kruis,Björn Ställberg,Rupert Jones,Ioanna Tsiligianni,Karin Lisspers,Thys van der Molen,Janwillem W. H. Kocks,Niels H. Chavannes +7 more
Reads0
Chats0
TLDR
Primary care COPD patients stand out from patients enrolled in LPCS in terms of gender, lung function, quality of life and exacerbations, as hitherto unknown GOLD I exacerbation characteristics are revealed.Abstract:
Background: Guideline recommendations for chronic obstructive pulmonary disease (COPD) are based on the results of large pharmaceutically-sponsored COPD studies (LPCS). There is a paucity of data on disease characteristics at the primary care level, while the majority of COPD patients are treated in primary care. Objective: We aimed to evaluate the external validity of six LPCS (ISOLDE, TRISTAN, TORCH, UPLIFT, ECLIPSE, POET-COPD) on which current guidelines are based, in relation to primary care COPD patients, in order to inform future clinical practice guidelines and trials. Methods: Baseline data of seven primary care databases (n = 3508) from Europe were compared to baseline data of the LPCS. In addition, we examined the proportion of primary care patients eligible to participate in the LPCS, based on inclusion criteria. Results: Overall, patients included in the LPCS were younger (mean difference (MD)-2.4; p = 0.03), predominantly male (MD 12.4; p = 0.1) with worse lung function (FEV1% MD -16.4; p = 1 and >= 2 exacerbations, although results were not statistically significant. Our findings add to the literature, as we revealed hitherto unknown GOLD I exacerbation characteristics, showing 34% of mild patients had >= 1 exacerbations per year and 12% had >= 2 exacerbations per year. The proportion of primary care patients eligible for inclusion in LPCS ranged from 17% (TRISTAN) to 42% (ECLIPSE, UPLIFT). Conclusion: Primary care COPD patients stand out from patients enrolled in LPCS in terms of gender, lung function, quality of life and exacerbations. More research is needed to determine the effect of pharmacological treatment in mild to moderate patients. We encourage future guideline makers to involve primary care populations in their recommendations.read more
Citations
More filters
Journal ArticleDOI
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
Claus Vogelmeier,Mina Gaga,Maryam Aalamian-Mattheis,Timm Greulich,Jose M. Marin,Walter Castellani,Vincent Ninane,Stephen Lane,Xavier Nunez,Francesco Patalano,Andreas Clemens,Konstantinos Kostikas +11 more
TL;DR: IND/GLY demonstrated superior improvements in lung function and dyspnoea after direct switch from previous treatments and better tolerability against LABA or LAMA monotherapies and combination of LABA and inhaled corticosteroid in patients with moderate COPD in several randomised controlled clinical trials.
Journal ArticleDOI
Socio-environmental correlates of physical activity in patients with chronic obstructive pulmonary disease (COPD)
Ane Arbillaga-Etxarri,Elena Gimeno-Santos,Anael Barberan-Garcia,Marta Benet,Eulàlia Borrell,Payam Dadvand,Maria Foraster,Alicia Marin,Mònica Monteagudo,Robert Rodriguez-Roisin,Pere Vall-Casas,Jordi Vilaró,Judith Garcia-Aymerich +12 more
TL;DR: Dog walking and grandparenting are associated with a higher amount and intensity of physical activity in COPD patients, and neighbourhood deprivation, surrounding greenness and proximity to green or blue spaces were not associated with physical activity.
Journal ArticleDOI
Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
TL;DR: By applying an extensive range of RCT selection criteria to a large, representative COPD patient population, this study highlights that the interpretation of results from RCTs must take into account that RCT participants are variably, but generally more representative of patients in the community than previously believed.
Journal ArticleDOI
The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group
Nicolas Roche,Antonio Anzueto,Sinthia Bosnic Anticevich,Sinthia Bosnic Anticevich,Alan Kaplan,Marc Miravitlles,Dermot Ryan,Joan B. Soriano,Omar S. Usmani,Nikolaos G. Papadopoulos,G. Walter Canonica +10 more
TL;DR: Randomised controlled trials (RCTs) are universally considered as the gold standard for evaluating the efficacy of treatments and can reach the highest level of internal validity, provided that all quality standards are followed, such as those defined by CONSORT guidelines.
Journal ArticleDOI
Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world, retrospective, observational.
Kevin Gruffydd-Jones,Guy Brusselle,Rupert Jones,Marc Miravitlles,Michael Baldwin,Rebecca Stewart,Anna Rigazio,Emily Davis,Dorothy L. Keininger,David Price +9 more
TL;DR: Comorbid asthma, a high exacerbation rate, increased symptoms and poor lung function each increased the likelihood of being prescribed any initial therapy or initial maintenance therapy; comorbid pneumonia and an annual rate of ⩾3 exacerbations were the strongest predictors.
References
More filters
Journal ArticleDOI
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
Jørgen Vestbo,Suzanne S. Hurd,Alvar Agusti,Paul W. Jones,Claus Vogelmeier,Antonio Anzueto,Peter J. Barnes,Leonardo M. Fabbri,Fernando J. Martinez,Masaharu Nishimura,Robert A. Stockley,Don D. Sin,Roberto Rodriguez-Roisin +12 more
TL;DR: It is recommended that spirometry is required for the clinical diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation.
Journal ArticleDOI
Global initiative for chronic obstructive lung disease.
Lynn B. Gerald,William C. Bailey +1 more
TL;DR: Representatives from many countries serve as a network for the dissemination and implementation of programs for diagnosis, management, and prevention of COPD.
Journal ArticleDOI
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Julie A. Anderson,Bartolome R. Celli,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Julie C. Yates,Jørgen Vestbo +6 more
TL;DR: The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance, and there were significant benefits in all other outcomes among these patients.
Journal ArticleDOI
The St George's Respiratory Questionnaire.
TL;DR: The St George's Respiratory Questionnaire is a standardized self-completed questionnaire for measuring impaired health and perceived well-being in airways disease and the background and rationale for its development are discussed together with an analysis of its performance.
Journal ArticleDOI
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
John R. Hurst,Jørgen Vestbo,Jørgen Vestbo,Antonio Anzueto,Nicholas Locantore,Hana Müllerová,Ruth Tal-Singer,Bruce E. Miller,David A. Lomas,Alvar Agusti,William MacNee,Peter M.A. Calverley,Stephen I. Rennard,Emiel F.M. Wouters,Jadwiga A. Wedzicha +14 more
TL;DR: Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype, which has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity.